Future Prospects And Stock Pricing Of Intellia Therapeutics Inc (NASDAQ: NTLA)

In the last trading session, 1.04 million shares of the Intellia Therapeutics Inc (NASDAQ:NTLA) were traded, and its beta was 1.77. Most recently the company’s share price was $27.51, and it changed around $0.49 or 1.81% from the last close, which brings the market valuation of the company to $2.64B. NTLA currently trades at a discount to its 52-week high of $47.48, offering almost -72.59% off that amount. The share price’s 52-week low was $22.67, which indicates that the current value has risen by an impressive 17.59% since then. We note from Intellia Therapeutics Inc’s average daily trading volume that its 10-day average is 1.18 million shares, with the 3-month average coming to 1.58 million.

Intellia Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.54. If we narrow it down even further, the data shows that 0 out of 28 analysts rate the stock as a Sell; another 8 rate it as Overweight. Among the rest, 5 recommended NTLA as a Hold, whereas 15 deemed it a Buy, and 0 rated it as Underweight. Intellia Therapeutics Inc is expected to report earnings per share of -$1.38 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Intellia Therapeutics Inc (NASDAQ:NTLA) trade information

Instantly NTLA has showed a green trend with a performance of 1.81% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -9.77% year-to-date, but still down -0.51% over the last five days. On the other hand, Intellia Therapeutics Inc (NASDAQ:NTLA) is -16.13% down in the 30-day period. We can see from the shorts that 13.5 million shares have been sold at a short interest cover period of 6.9 day(s).

The consensus price target as assigned by Wall Street analysts is $131.76, which translates to bulls needing to increase their stock price by 79.12% from its current value. Analyst projections state that NTLA is forecast to be at a low of $54 and a high of $252.

Intellia Therapeutics Inc (NTLA) estimates and forecasts

Intellia Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -14.27 percent over the past six months and at a -2.95% annual growth rate that is well below the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -17.90% in revenue this quarter, and will report an increase of 7.90% in the next quarter. The year-over-year growth rate is expected to be 39.80%, up from the previous year.

Consensus estimates provided by 16 financial analysts predict the company will bring in an average of $11.5 million in revenue for the current quarter. 19 analysts expect Intellia Therapeutics Inc to make $20.29 million in revenue for the quarter ending Jun 2024. Forecasts for the next quarter put sales growth at 68.00%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -22.30%. Intellia Therapeutics Inc earnings are expected to increase by -2.56% in 2024, but the outlook is positive 30.00% per year for the next five years.

NTLA Dividends

Intellia Therapeutics Inc’s next quarterly earnings report is expected to be released around May 02 and May 06.

Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.33% of Intellia Therapeutics Inc shares, and 87.34% of them are in the hands of institutional investors. The stock currently has a share float of 88.52%. Intellia Therapeutics Inc stock is held by 424 institutions, with ARK Investment Management, LLC being the largest institutional investor. By Sep 29, 2023, it held 11.24% of the shares, which is about 9.95 million shares worth $314.58 million.

Vanguard Group Inc, with 9.25% or 8.19 million shares worth $333.79 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 29, 2023. The former held 6.78 million shares worth $214.49 million, making up 7.67% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.62 million shares worth around $107.02 million, which represents about 2.97% of the total shares outstanding.